Five-Year Mortality in Colorectal Cancer Patients with Ulcerative Colitis or Crohnʼs Disease

Ording, Anne Gulbech; Horváth‐Puhó, Erzsébet; Erichsen, Rune; Long, Millie D.; Baron, John A.; Lash, Timothy L.; Sørensen, Henrik Toft

doi:10.1097/mib.0b013e3182802af7

Cited by 72 publications

(47 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…First, it has been shown that diseases, such as diabetes and inflammatory bowel disease, increase CRC risk, and it has been speculated that this association might result in particularly aggressive CRC with poor survival (Ording et al , 2013). Had this been true, we would have expected to observe interaction between CRC and comorbidities also after the first year of follow-up, which we did not.…”

Section: Discussionmentioning

confidence: 99%

Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study

et al. 2013

View full text Add to dashboard Cite

Background:It is unknown whether comorbidity interacts with colorectal cancer (CRC) to increase the rate of mortality beyond that explained by the independent effects of CRC and comorbid conditions.Methods:We conducted a cohort study (1995–2010) of all Danish CRC patients (n=56 963), and five times as many persons from the general population (n=271 670) matched by age, gender, and specific comorbidities. To analyse comorbidity, we used the Charlson Comorbidity Index (CCI) scores. We estimated standardised mortality rates per 1000 person-years, and calculated interaction contrasts as a measure of the excess mortality rate not explained by the independent effects of CRC or comorbidities.Results:Among CRC patients with a CCI score=1, the 0–1 year mortality rate was 415 out of 1000 person-years (95% confidence interval (CI): 401, 430) and the interaction accounted for 9.3% of this rate (interaction contrast=39 out of 1000 person-years, 95% CI: 22, 55). For patients with a CCI score of 4 or more, the interaction accounted for 34% of the mortality (interaction contrast=262 out of 1000 person-years, 95% CI: 215, 310). The interaction between CRC and comorbidities had limited influence on mortality beyond 1 year after diagnosis.Conclusion:Successful treatment of the comorbidity is pivotal and may reduce the mortality attributable to comorbidity itself, and also the mortality attributable to the interaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Furthermore, the progression from inflammation to atypical hyperplasia to cancer in patients with UC is more rapid than the progression of adenoma to adenocarcinoma in the general population (8,9). Thus, as an independent risk factor, intestinal inflammation is the initial step in UC-CRC development, and the risk of CRC increases with the severity of inflammation in patients with atypical hyperplasia or chronic UC.…”

Section: Introductionmentioning

confidence: 99%

Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis

Wang

Liu

Guo

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

The effects of indigo naturalis (IN), which is a traditional Chinese herbal formulation, have been clinically demonstrated in treating refractory ulcerative colitis (UC). The present study aimed to verify the effects and mechanisms of IN in experimental UC rats. A total of 48 male Sprague-Dawley rats were randomly divided into six groups: Chow, model, high-dose IN, medium-dose IN, low-dose IN and mesalazine (a bowel-specific aminosalicylate drug) groups. The models were administered 3.5% dextran sodium sulphate solution for 7 days. The treatment groups were administered IN or mesalazine and then sacrificed and sampled on day 8. Disease activity index (DAI), histological damage score (HDS) and myeloperoxidase (MPO) activity were used to evaluate the severity of UC. Colon and serum cytokines were detected using liquid-phase chip technology and the expression of occludin protein in colonic mucosa was assessed by immunohistochemistry and western blot analysis. The results indicated that the oral administration of IN may reduce DAI, HDS and MPO activity. IN also reduced the expression of inflammatory cytokines and increased the expression of colonic mucosal repair-related cytokines and occludin protein. These results highlight the potential of IN as a therapeutic agent for treating UC through its action of inflammation control and colonic mucosal damage repair.

show abstract

“…The genetic and histopathologic differences between IBD‐related and sporadic CRC suggest that the two may also demonstrate distinct clinical behavior. To this end, several studies have compared long‐term outcomes of sporadic versus colitis‐associated CRC with inconsistent results . Nonetheless, to our knowledge, no study to date has explicitly assessed the outcomes of patients with IBD‐related CRC and resectable colorectal liver metastases (CRLM) or compared them with the long‐term outcomes of patients with resectable sporadic CRLM.…”

Section: Introductionmentioning

confidence: 99%

The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis

Margonis

Buettner

Andreatos

et al. 2018

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and Objectives In contrast with sporadic colorectal cancer liver metastases (CRLM), inflammatory bowel disease (IBD)‐related CRLM have not been studied to date. Methods Patients who underwent resection for IBD‐related and sporadic CRLM from 2000 to 2015 were identified from an international registry and matched for pertinent prognostic variables. Overall survival (OS) and recurrence‐free survival (RFS) were subsequently assessed. Results Twenty‐eight patients had IBD‐related CRLM. Synchronous extrahepatic disease was more common in IBD‐related CRLM patients than patients with sporadic CRLM (28.6% vs 8.3%; P < 0.001), most commonly located in the lungs. In multivariable analysis, IBD did not have a significant influence on OS ( P = 0.835), and had a hazard ratio (HR) close to 1 (HR, 0.95; 95% confidence interval [CI], 0.57‐1.57). IBD was also not associated with inferior RFS (HR, 1.07; 95%CI, 0.68‐1.68; P = 0.780). Among patients with IBD‐related CRLM, 9(50%) had isolated intrahepatic recurrence and 8(44.4%) isolated extrahepatic recurrence, while only 1(5.6%) developed combined recurrence. Of those who experienced recurrence after resection of IBD‐related CRLM, 10 had their recurrence treated with curative intent. Conclusions Patients with IBD‐related CRLM had similar survival compared with patients with sporadic CRLM, even though they more often present with extrahepatic disease. In addition, patients with IBD‐related CRLM may experience patterns of recurrence different from patients with sporadic CRLM.

show abstract

Five-Year Mortality in Colorectal Cancer Patients with Ulcerative Colitis or Crohnʼs Disease

Abstract: A history of IBD in patients with CRC may be associated with increased mortality.

Cited by 72 publications

References 30 publications

Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study

Does comorbidity interact with colorectal cancer to increase mortality? A nationwide population-based cohort study

Effects of indigo naturalis on colonic mucosal injuries and inflammation in rats with dextran sodium sulphate-induced ulcerative colitis

The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis

Contact Info

Product

Resources

About